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Abstract
AIM: To identify the variants in UDP-glucuronosyltransfe-
rase 1 (UGT1A1) gene in Gilbert’s syndrome (GS) and to 
estimate the association between homozygosity for TA 
insertion and GS in India, as well as the frequency of TA 
insertion and its impact among normal controls in India. 
METHODS: Ninety-fi ve GS cases and 95 normal controls 
were selected. Liver function and other tests were 
done. The promoter and all 5 exons of UGT1A1 gene 
were resequenced. Functional assessment of a novel 
trinucleotide insertion was done by in silico  analysis and 
by estimating UGT1A1 promoter activity carried out by 
luciferase reporter assay of appropriate constructs in Hep 
G2 cell line.
RESULTS: Among the GS pat ien ts , 80% were 
homozygous for the TA insertion, which was several-fold 
higher than reports from other ethnic groups. The mean 
UCB level was elevated among individuals with only 
one copy of this insertion, which was not significantly 
different from those with two copies. Many new DNA 
variants in UGT1A1 gene were discovered, including a 
trinucleotide (CAT) insertion in the promoter found in 
a subset (10%) of GS patients, but not among normal 
controls. In-silico  analysis showed marked changes in 
the DNA-folding of the promoter and functional analysis 
showed a 20-fold reduction in transcription efficiency 
of UGT1A1 gene resulting from this insertion, thereby 
signifi cantly elevating the UCB level.
CONCLUSION: The genetic epidemiology of GS 
is variable across ethnic groups and the epistatic 
interactions among UGT1A1 promoter variants modulate 
bilirubin glucuronidation.
© 2006 The WJG Press. All rights reserved.
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INTRODUCTION
Gilbert’s syndrome (GS) is generally considered to be 
an autosomal recessive disorder (OMIM #143500) 
cha rac t e r i zed by mi ld , ch ron i c , non-hemoly t i c 
unconjugated hyperbilirubinemia in the absence of  
liver disease. Although it has long been perceived to 
be an innocuous clinical entity with a benign course, 
recent data suggest that affected individuals may be 
predisposed to development of  liver injury following 
treatment with various drugs and xenobiotics and that 
the genetic defect in GS may influence the outcome of  
liver transplantation and other clinical conditions. The 
disorder due to a defi ciency in bilirubin glucuronidation, 
is commonly caused by dinucleotide (TA) insertions and 
[TA (TA)7TAA] alleles in the promoter region of  the 
bilirubin UDP-glucuronosyltransferase 1 (UGT1A1) 
gene. This dinucleotide insertion reduces the efficiency 
of  transcription of  the gene and decreases hepatic UDP-
glucuronosyltransferase activity to about 30% of  normal 
levels in homozygous subjects[6-9]. The prevalence of  GS, 
the frequency of  the (TA)7TAA allele in the UGT1A1 
promoter and the proportion of  GS patients who 
are homozygous for the (TA)7TAA allele vary widely 
across populations[10-19]. Recent data have also shown 
that variants in UGT1A1 gene other than the classical 
dinucleotide insertion in its promoter, can contribute 
to hyperbilirubinemia, including the milder form as in 
GS, although their effects appear to be variable across 
populations[5,20-24]. Thus, as recently emphasized[20], 
detailed investigations into genetic polymorphisms of  
UGT1A1 gene in Asian populations may provide a better 
understanding of  unconjugated hyperbilirubinemia.
    The objectives of  our case-control study were to 
estimate the association between homozygosity for the 
(TA)7TAA allele and GS in India, to identify and study the 
impact of  this and other polymorphisms in the promoter 
and exons of  the UGT1A1 gene on serum bilirubin 
levels, and to estimate the frequency of  the (TA)7TAA 
homozygous genotype in the general population in India.
MATERIALS AND METHODS
Participant recruitment and clinical biochemistry analysis
This study was conducted in 95 consecutive patients 
presenting to the Liver Clinic at the Department of  
Gastroenterology of  the Institute of  Postgraduate Medical 
Education & Research, Kolkata, India, for evaluation 
of  persistent unconjugated hyperbilirubinemia (serum 
bilirubin greater than 1.2 mg/dL) documented at least 
twice over a period of  one month. Serum total bilirubin 
and its unconjugated fraction were estimated in fasting 
condition. Each of  these individuals had a normal fi nding 
on physical examination, normal hepatobiliary ultrasound, 
normal liver function test excluding hyperbilirubinemia 
and a normal reticulocyte count. A total of  95 adult 
healthy volunteers from the same ethnic population as 
the GS patients were included as controls. Each control 
also underwent the same set of  investigations as the 
patients. Their fasting serum bilirubin level estimated 
twice at intervals of  fi fteen days was consistently less than 
1.0 mg/dL. Patients were excluded if  they were under 
any medication during the past one month or consumed 
alcohol regularly or had present or past history of  
hepatic/hematological disease. Additionally, quantitative 
estimation of  hemoglobin fractions (A0, A2 and F) was 
carried out on each patient and control by cation-exchange 
HPLC using the VariantTM Hemoglobin Testing System 
Beta Thalassemia Short Program (Bio-Rad Diagnostics, 
Hercules, USA). A 5 mL blood sample was collected 
from each patient by venipuncture and DNA was isolated 
using a standard protocol[25]. Data and samples were 
collected with written informed consent of  the patients 
and controls, after the approval was obtained from the 
Human Research Ethics Committee of  the Institute of  
Postgraduate Medical Education & Research, Kolkata. 
DNA re-sequencing and identifi cation of variant alleles
DNA re-sequencing of  the promoter and exon 1*1 
encoding the substrate-specifi c region of  bilirubin-UGT1 
gene as well as the 4 common exons (exons 2-5) was 
carried out using an automated DNA sequencer (ABI-3100; 
Applied Bio-systems, Foster City, USA.). DNA samples 
were first amplified by the polymerase chain reaction 
technique using an ABI-9700 thermal cycler. PCR products 
were then cleaned using exonuclease-I (USB. Corporation, 
Cleveland, USA) and shrimp alkaline phosphatase 
(Amersham, Freiburg, Germany), and sequencing reactions 
were carried out. DNA resequencing was carried out in 
both forward and reverse directions. Raw DNA sequences 
were analyzed as previously described[26], and variant 
genotypes were identifi ed.
Functional analysis of a novel trinucleotide insertion by 
luciferase reporter assay
UGT1A1 promoter fragments, 331-336 bp in length 
depending on the number of  TA repeats and CAT 
insertion, were amplifi ed using primers (F: 5’-tgtagatcttcct
ctctggtaacact-3’) and (R: 5’-atgaagctttgctcctgccagaggttc-3’) 
from genomic DNA of  individuals homozygous for six 
and seven TA repeats, and CAT insertion on (TA)7TAA 
background. DNA amplification was carried out with 
polymerase chain reaction (PCR) using FastStart Taq 
DNA polymerase (Roche, Mannheim, Germany) with an 
initial denaturation at 95 ℃ for 10 min, followed by 35 
cycles at 94 ℃ for 1 min, at 56 ℃ for 45 s and at 72 ℃ for 
30 s on an ABI-9 700 (Applied Bio-systems, Foster City, 
USA.) thermal cycler. To facilitate subcloning of  the PCR 
products in the reporter gene construct, oligonucleotides F 
and R were designed with a Bgl II and a Hind III restriction 
enzyme site at the 5’ end, respectively. PCR products 
were doubly digested with Bgl II and Hind III, purifi ed by 
Qiagen gel purifi cation kit (Qiagen, Hilden, Germany) and 
subcloned into pGL3-basic vector (Promega, Madison, 
USA). The integrity of  the resulting plasmids was 
confi rmed by restriction mapping and sequencing analyses. 
Promoter activity of  each construct was measured in 
HepG2 cell line. Cells were grown in MEM medium 
supplemented with 2 mmol/L L-glutamine, 0.1 mmol/L 
non-essential amino acids, 1 mmol/L sodium pyruvate and 
10% fetal calf  serum (GIBCO -BRL, Grand Island, USA) 
at 37 ℃ with 50 mL/L CO2. Exponentially growing cells 
were trypsinized, seeded at 2.5×105 cells, and incubated 
overnight prior to transfection. Transfection was carried 
out by lipofectamin (Invitrogen, Carlsbad, USA) using 2 
μg of  each of  the constructs (namely (TA)6 TAA, (TA)7 
TAA and CAT insertion on (TA)7 TAA background), 
as well as the pGL3-basic and pGL3-control as positive 
controls (TA)7TAA, the luciferease gene was under the 
control of  SV40 promoter and enhancer. After 48 h of  
transfection, the cells were lysed and centrifuged in cell 
culture lysis buffer (Promega, Madison, USA). Luciferase 
activity was assayed in the cell lysate by measuring the 
photoluminescence in a Monolight 2010 single channel 
luminometer and the total cellular protein content was 
measured by the standard Bradford’s method. Luciferease 
activity was normalized to total cell protein concentration. 
Normalized luciferase activity of  each construct was 
expressed as a ratio to that of  the pGL3-basic vector. 
Three independent experiments were performed for 
each construct and all measurements were determined in 
duplicate.
Statistical analysis
Equality of  proportions was statistically tested by the 
standard normal test procedure[27]. Equalities of  mean 
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values of  various hematological parameters for individuals 
belonging to different genotypes at various polymorphic 
loci were statistically tested using the Student t-test or the 
analysis of  variance (ANOVA) procedure, as appropriate. 
Regression analysis was performed to test the signifi cance 
of  dependence of  un-conjugated serum bilirubin level on 
some relevant variables. Allele frequencies were estimated 
using the gene-counting method. 
RESULTS
Characteristics of patients and controls
No statistically significant (P > 0.05) differences in the 
proportions of  males and females were observed between 
the patients (87 males, 8 females) and controls (77 males, 
18 females). The mean ages of  male and female patients 
(30.1 ± 1.1 years of  males, 26.8 ± 5.1 years of  females) 
and controls (30.2 ± 1.1 years of  males, 31.1  ± 2.9 years 
of  females) were not significantly different (P > 0.05). 
Since elevated HbA2 levels could potentially increase the 
unconjugated bilirubin level, we tested the signifi cance of  
the regression coeffi cient of  HbA2 level on unconjugated 
bilirubin, separately for patients and controls. In both 
sets, there was no statistically significant impact of  
HbA2 (P-values for patients and controls were 0.638 
and 0.106, respectively). The difference in the mean 
values of  HbA2 between patients and controls was not 
signifi cantly different (t = 1.76, d.f. = 128, P > 0.05). The 8 
GS patients, but none of  the normal controls, who were 
habitual smokers were asked to refrain from smoking 
for 24 h prior to blood collection. We tested whether 
the inclusion of  these 8 GS patients had a significant 
impact on our fi ndings. We therefore, examined whether 
the mean value of  un-conjugated bil irubin among 
patients who were smokers (n = 8) was significantly 
higher than that among patients who were not smokers 
(n = 87). No significant difference was found (mean for 
smoker patients=2.67 ± 0.33, mean for non-smoker 
patients = 3.38 ± 0.30, t = 0.696, d.f. = 93, P = 0.488). We 
have performed all analyses that were reported below with 
and without the inclusion of  the 8 GS patients who were 
habitual smokers. No differences in inferences were found 
(results not shown). Therefore, we presented all results 
including these 8 GS subjects.
UGT1A1 sequence variants and their relation with bilirubin 
level
Eleven sequence variants in UGT1A1 gene was observed, 
of  which 3 each were in the promoter, 3 in exon 1, 2 in 
exon 2, 1 in exon 3 and 2 in exon 4. No variant was found 
in exon 5. The genotype and variant allele frequencies at 
these positions in patients and controls are given in Table 
1. Of  these 11 variant sites, 2 were non-polymorphic 
(frequency of  the rarer allele < 1%), while the remaining 
9 sites were polymorphic either among patients or among 
controls or in both. One of  the polymorphic sites was the 
TA insertion [(TA)7TAA allele] in the TATA box of  the 
UGT1A1 promoter[2,3]. The frequencies of  the (TA)7TAA 
allele (0.879) and the 7/7 genotype (80%) among the 
patients were significantly higher (P < 0.005) than those 
among the controls (0.384 and 10%, respectively). The 
un-conjugated serum bilirubin values for GS patients 
belonging to the 6/6, 7/6 and 7/7 genotypes are presented 
in Figure 1. The mean values of  un-conjugated bilirubin 
for GS patients and normal controls were 2.5 ± 0.25 
mg/dL and 0.61 ± 0.09 mg/dL respectively. The mean+SE 
value of  un-conjugated bilirubin among patients with 
the 7/6 genotype was 3.46 ± 0.54 mg/dL, which was not 
signifi cantly different (P = 0.05) from patients with the 7/7 
genotype (3.31 ± 0.33 mg/dL). The mean un-conjugated 
serum bilirubin values for these genotypes among controls 
were only 0.59 ± 0.10 mg/dL and 0.64 ± 0.15 mg/dL, 
respectively. 
    No significant differences (P = 0.05) were found in 
the mean bilirubin levels among individuals belonging 
to the var ious genotypes at the remaining s ingle 
nucleotide polymorphic loci. With respect to the C6844G 
polymorphism resulting in a non-synonymous amino 
acid change (A321G), all patients were CC homozygotes, 
while about 30% of  the controls were CG heterozygotes 
(Table 1). We did not find any significant effect of  the 
G71R polymorphism on un-conjugated bilirubin level. 
This polymorphism also showed no signifi cant interaction 
with the TATA box insertion polymorphism (results not 
shown). These fi ndings are discordant with those reported 
among the Japanese[19].
A novel human-specifi c trinucleotide insertion in Gilbert’s 
syndrome patients and its impact on bilirubin level 
Among the polymorphic variants described in Table 1, 
aside from the familiar TA insertion, the most striking 
was the CAT insertion (nucleotide positions -85 to -83) 
in the CAAT box of  UGT1*1 promoter. Normally, there 
is one copy of  the CAT trinucleotide present in human 
Genbank (http://www.ncbi.nlm.nih.gov/Genbank/). 
We found two copies of  this trinucleotide in some GS 
patients. To confi rm that this was an insertion we searched 
the chimpanzee (gi|6456543|gb|AF135463.1|AF135463) 
and gorilla (gi|6456545|gb|AF135464.1|AF135464) 
databases. In both species there is only copy, confi rming 
that the single copy is the ancestral state. This CAT 
insertion was found only among nine (10%) GS patients, 
who were all homozygous for the TA insertion. We found 
that GS patients with the CAT-insertion had a signifi cantly 
(P < 0.001) elevated mean level (6.13 ± 1.61 mg/dL) 
compared to those without the insertion (2.93 ± 0.28 
mg/dL). Individuals who possessed the CAT insertion did 
not consistently possess a variant allele at any of  the other 
sites. One individual who was heterozygous for the CAT 
insertion was also heterozygous for the I322V variant, 
and other three CAT-insertion heterozygotes were also 
heterozygotes for the H376R variant.
Functional analysis of CAT insertion
Since about 10% of  the (TA)7TAA homozygotes carried 
the CAT insertion and the insertion signifi cantly elevated 
the bilirubin level, we postulated that the insertion had a 
functional impact. To examine this, we studied the change 
in DNA-folding of  the promoter region caused by this 
insertion. The most stable structures, namely those with 
lowest free energy (dG) values, are given in Figure 2 for 
the UGT1A1 promoter region without (dG = -14.4) and 
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with (dG = -14.8) the additional CAT insertion. A striking 
structural change was found around the region of  the 
insertion, the loops were converted to stems. It is well 
known that formation of  stems in the promoter could 
reduce transcription of  the gene. A detailed functional 
analysis of  the UGT1A1 promoter by luciferase reporter 
assay confirmed that there was a two-fold decrease 
in transcription efficiency for the variant (TA)7TAA 
promoter allele, and a 20-fold decrease when there was 
a CAT insertion in the promoter on the background of  
the (TA)7TAA allele compared to the normal (TA)6TAA 
promoter allele (Figure 3). 
DISCUSSION
Genetically determined un-conjugated hyperbilirubinemia 
constitutes a spectrum of  clinical entities characterized 
by incremental serum bilirubin values related to graded 
reduction of  UGT1A1 enzyme activity. The most 
novel finding of  our study is that a trinucleotide (CAT) 
insertion in the nucleotide positions -85 to -83 of  the 
UGT1A1 promoter was present in GS patients who were 
homozygous for the causal TA insertion, but not in other 
GS patients or in controls. This insertion significantly 
(P < 0.001) elevated the un-conjugated bilirubin level 
(mean = 6.13 mg/dL) in the patients to the range usually 
seen in Crigler-Najjar (CN) II syndrome. We have 
Table 1 DNA sequence variations observed among Gilbert’s syndrome patients and normal controls
Location of variant and
nucleotide position (np) Description of variant
1 Genotype/Allele frequency (p) Patients (%) Control (%)
UGT1*1 promoter CAT insertion Insertion/Insertion   3   0
nps -85 to -83 Insertion/non-insertion   6   0
Non-insertion/non-insertion 86 95
p(Insertion)   0.063   0.000
UGT1*1 promoter G→C GG 93 95
np -63 GC   2   0
p(C)   0.011   0.000
UGT1*1 promoter (TA)6 TAA→ (TA)6 TAA /(TA)6 TAA   4 32
nps -53 to -38 (TA)7 TAA (TA)7 TAA /(TA)6 TAA 15 53
(TA)7 TAA/(TA)7 TAA 76 10
p[(TA)7 TAA]   0.879   0.384
Exon 1 G→A GG 85 90
np +211 (G71R) GA   9   5
AA   1   0
p(A)   0.058   0.026
Exon 1 T→C TT 93 94
np +476 (I159T) TC   2   1
p(C)   0.011   0.005
Exon 1 T→C TT 94 95
np +625 (R209W) TC   1   0
p(C)   0.005   0.000
Exon 2 C→G CC 95 66
np +6 844 (A321G) CG   0 29
p(G)   0.000   0.152
Exon 2 A→G AA 87 89
np +6 846 (I322V) AG   7   6
GG   1   0
p(G)   0.042   0.032
Exon 3 G→A GG 94 95
np +7 640 (D359N) GA   1   0
p(A)   0.005   0.000
Exon 4 C→T CC 93 95
np +7 939 (P364L) CT   2   0
p(T)   0.011   0.000
Exon 4 A→G AA 92 95
np +7 975 (H376R) AG   3   0
p(G)   0.016   0.000
1Amino acid changes resulting from nucleotide changes in the exons are indicated in parentheses.
Figure 1 Distributions of un-conjugated serum bilirubin values among Gilbert’s 
syndrome patients classifi ed by the genotype of the common TA insertion in the 
TATA box of the UGT1A1 promoter.
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demonstrated that this insertion in the background of  
the (TA)7 allele classically described in GS, diminishes 
UGT1A1 transcriptional activity to about 5% (2.4 light 
units/103 μg protein) of  the normal (44.9 light units/103 μg 
protein), much lower than the 50% reduction (22.9 light 
units/103 μg protein) observed for (TA)7 alone. Thus the 
combined biological effect of  the CAT and TA insertions 
is a further elevation in the un-conjugated bilirubin 
level compared to that of  the TA insertion alone, which 
is exactly what we have observed in the GS patients 
carrying the CAT insertion. This initial description of  
the interactive infl uence of  a novel trinucleotide insertion 
and the GS-type abnormality in the promoter region 
alone, in the absence of  a consistent exonic mutation, 
to quantitatively elevate un-conjugated bilirubin to levels 
observed in Crigler-Najjar II (CN II) provides further 
evidence of  genetic heterogeneity and overlap of  the 
clinical syndromes of  un-conjugated hyperbilirubinemia. 
Thus, Gilbert’s, Crigler-Najjar I (CN I) and CN II 
syndromes may not be mutually exclusive clinical-genetic 
entitities but are different windows of  the quantititative 
spectrum of  elevated serum unconjugated bilirubin levels. 
    The associat ion (80%) between homozygosity 
for the (TA)7TAA allele and GS is much stronger in 
India than reported earlier from most other ethnic 
groups[14,15,16,20]. Graded reduction of  UGT1 activity has 
been demonstrated with increasing length of  the TA 
repeats in a recent study[28]. It was demonstrated that 7/7 
homozygotes and 7/6 heterozygotes have, respectively, a 
52% and a 37% reduction of  UDP glucuronyl transferase 
activity in liver tissue homogenates. In our study, serum 
un-conjugated bilirubin values among 7/6 heterozygote 
GS patients were high but not signifi cantly different from 
the 7/7 homozygotes. The finding of  increased serum 
bilirubin values among the 7/6 heterozygote GS patients 
to the same extent as those homozygous for the classically 
described 7/7 genotype, even in the absence of  any other 
consistent change in the UGT1A1 gene, is intriguing. We 
could not explain this finding, but speculate the role of  
other interacting non-UGT1A1 genetic variants. 
    Although the insertion of  additional TA repeats in the 
(TA)6 TAA promoter, sequence of  the UGT1A1 gene 
is the most common variation associated with Gilbert’s 
syndrome, (TA)5 and (TA)8  sequences in the TATAA 
box have also been found[4,14]. We did not find (TA)5 
and (TA)8 alleles in our study participants. Moreover, 
several mutations in the exons have been found in other 
populations, particularly from Asia, in association with GS 
and hyperbilirubinemia, either as the only abnormality or 
in addition to the more common promoter defect[20-22,29-31]. 
We have identified several promoter and coding region 
(all non-synonymous) variants of  the gene (Table 1). 
The G71R variant has been reported earlier[19, 22-24], and 
the P364L variant has recently been reported in one 
Japanese GS patient[19]. Contrary to the finding among 
the Japanese[32], the G71R change had no impact on un-
conjugated bilirubin level in our samples, nor did it interact 
with the dinucleotide (TA) insertion in the TATA box of  
the UGT1A1 gene. Many variants discovered in this study 
have not been reported earlier and many variants reported 
earlier were not found in the present sample. Although all 
the observed variations in exons could result in amino acid 
substitutions, none of  these signifi cantly altered the mean 
bilirubin level. Thus, the UGT1A1 gene appears to tolerate 
a large number of  mutations without any significant 
deleterious effect. None of  these was strongly associated 
with the (TA)7TAA allele in our study. However, the amino 
acid change from isoleucine to valine at the amino acid 
position 322 was only found among the controls and not 
among the GS patients. Further studies are necessary to 
test whether this change helps bilirubin glucuronidation by 
the UGT1A1 gene. 
    The UGT1A1 polymorphisms have recently acquired 
signifi cance because they predispose individuals to altered 
metabolism and enhanced toxicity of  several drugs like 
paracetamol, propofol, irinotecan, indinavir, etc, which are 
Figure 3 Transcriptional activities of the (TA) 6TAA, (TA)7 TAA and CAT alleles as 
assessed by a luciferase reporter assay.
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substrates for glucoronidation by UGT1A1[33-36]. Exons 
2-5 are shared by other UGT1A transcripts and isozymes 
that mediate metabolism of  xenobiotics apart from A1 
involved in bilirubin glucuronidation[37]. The new variants 
in these exons may be relevant to drug metabolism, but we 
have not tested this. Our fi ndings reveal that it is crucial 
to carry out detailed surveys on genetic variations in and 
around the UGT1A1 gene and functional studies on 
these variants for a deeper understanding of  quantitative 
anomalies of  bilirubin. 
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